drug
onasemnogene abeparvovec
Marketedupdated 6mo agoby Novartis Gene Therapies
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying onasemnogene abeparvovec
- phase4ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM)
- phase3Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
- phase3Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies
- phase3Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
- phase3Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
- phase3Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
- phase1Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy
- phase3Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
News(3)
- Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivalsFull data from the Phase 3 HORIZON trial of Novartis' pelacarsen failed to show any apparent benefit, leading analysts to further reduce the odds of success for Lp(a)-lowering competitors such as A…biospace · 9d ago
- Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturingThe BioSpace 40 Under 40 honoree helped steer Forge’s sale to Ajinomoto. Now, Samantha Piteri-Molina sees opportunities in AI-driven analytics and Ohio’s gene therapy ecosystem—with a responsibilit…biospace · 12d ago
- MedWatch Alert: FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene TherapyFDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy: FDA Safety Communicationfda_medwatch · 13d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that